Shortening Overall Treatment to 12 Weeks of Simeprevir (SMV) Plus PEG-IFN/RBV in Treatment-Naïve Chronic Hepatitis C (CHC) Genotype 1 Patients: Assessment of Baseline and Week 2 On-Treatment Predictors of SVR

M Gschwantler,T Asselah, C Moreno,C Sarrazin,GR Foster,A Craxi,P Buggisch,R Ryan,O Lenz,G Van Dooren,I Lonjon-Domanec,M Schlag,M Buti

Zeitschrift für Gastroenterologie（2015）

引用 0|浏览14

暂无评分

摘要

Purpose: To assess whether Week-2 response with SMV+Peg-IFN/RBV can allow shortening treatment to 12 weeks, irrespective of baseline and on-treatment factors.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要